Investigation of the expression of Long non-coding RNA in Parkinson's disease

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Abstract Background and aim Parkinson's disease is the second chronic age-related neurodegenerative disease after Alzheimer's. Pathogenic factors in Parkinson's include inflammation and oxidative stress, which lead to dopaminergic cell apoptosis. The case-control study aims to determine the expression level of long non-coding RNAs (lncRNAs) of the apoptosis pathway in Parkinson's patients with healthy individuals. Methods In the case-control study, 50 patients with Parkinson's disease were examined, with 50 healthy individuals matched in age and sex. In both groups, the expression of long non-coding RNAs includes taurine up-regulated 1(TUG1), metastasis associated lung adenocarcinoma transcript 1(MALAT1) ،nuclear enriched abundant transcript 1(NEAT1), and Growth Arrest Specific 5(GAS5) were compared using Real-time polymerase chain reaction (PCR.) Results MALAT1, NEAT1, and TUG1 gene expression ratio in the case group was statistically significantly higher than in healthy individuals. The ratio of GAS5 gene expression in people with Parkinson's disease was lower, with a statistically significant difference. The ratio of HULC gene expression was higher in the case group, but it did not show a statistically significant difference with the control group. Conclusion The involvement of long lncRNAs that increase apoptosis may play a role in the pathogenesis of the disease, which may be used for identification and therapeutic purposes.

Related topics